The agency is doubling down on a bad guidance that endangers access to important medicines. Action Alert! Recently, the FDA announced the withdrawal of Compliance Policy Guide 400.400, a document that had been in place since 1988 and which established the agency’s enforcement policies regarding homeopathic medicines. In its place, the FDA has issued a… Continue reading FDA Renews Attack on Homeopathy
Author: ANHUSA
CAFOs Are Gaming Organic Standards
The USDA is considering a rule that would help close loopholes, but it doesn’t go far enough. Action Alert! The USDA’s National Organic Program (NOP) has reopened the comment period on the 2015 Origin of Livestock proposed rule that attempts to prevent large, industrial dairy and cattle operations from gaming the system. While the rule… Continue reading CAFOs Are Gaming Organic Standards
“Approved” “Hormone Therapy” For Women is Mostly Not Bio-Identical, is “One-Size-Fits-All,” and Not Safe for Use
The following article is by Dr. Jonathan V. Wright. The original article appears in the November 2019 issue of the Green Medicine Newsletter. Action Alert! The September 24th issue of the Journal of the American Medical Association (“JAMA”) reprinted[1] an article originally published in The Medical Letter on Drugs and Therapeutics which told us about the… Continue reading “Approved” “Hormone Therapy” For Women is Mostly Not Bio-Identical, is “One-Size-Fits-All,” and Not Safe for Use
TDF drugs damage the kidneys and bones
TDF drugs are antiretrovirals used to treat HIV. Gilead Sciences markets TDF in combination with other drugs under the brand name Truvada, as well as other names such as Atripla, Complera, Stribild, Symfi-Lo, Cimduo and Viread. Studies have found TDF drugs to be damaging to the kidneys and bones—dangers that were not properly disclosed to… Continue reading TDF drugs damage the kidneys and bones
Proton Pump Inhibitors (PPIs) and kidney disease
Millions of Americans have taken PPIs like Prilosec, Nexium and Prevacid to treat heartburn. These drugs have been promoted as a safe and more effective alternative to other antacid treatments and have been widely prescribed. These drugs, however, can allegedly cause extensive kidney damage. Numerous studies have shown the potential for injury from PPI use,… Continue reading Proton Pump Inhibitors (PPIs) and kidney disease
Incretin Mimetics and pancreatic complications
Incretin mimetics are a class of drugs used to Type 2 diabetes. Recent studies have shown that incretin mimetics are linked with pancreatic cancer. In 2013, the FDA released unpublished academic research that demonstrated pre-cancerous cellular changes known as pancreatic duct metaplasia in Type 2 diabetic patients treated with incretin mimetics. Incretin mimetics act like… Continue reading Incretin Mimetics and pancreatic complications
Taxotere and permanent hair loss
Taxotere is a plant alkaloid chemotherapy drug derived from the yew tree. Taxotere is used intravenously in patients with locally advanced or metastatic breast cancer (after failure of prior chemotherapy) and in conjunction with doxorubicin and cyclophosphamide in patients with operable node-positive breast cancer. Unfortunately, it appears as though Taxotere is no more effective than… Continue reading Taxotere and permanent hair loss
Valsartan and cancer, liver damage
Valsartan is an angiotensin-receptor blocker which is prescribed to patients with high blood pressure or congestive heart failure. Valsartan is widely manufactured overseas. Unfortunately, the Food and Drug Administration (FDA) has found Valsartan drugs made by generic manufacturers to be contaminated with N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA). These impurities may have the potential to cause… Continue reading Valsartan and cancer, liver damage
Xeljanz and pulmonary embolism and thrombosis
Xeljanz is a drug used to treat rheumatoid arthritis and ulcerative colitis. Unfortunately, after Xeljanz was approved the FDA issued a safety warning on the drug, regarding an increased risk of blood clots and of death with the 10 mg twice daily dose of Xeljanz. If you have taken the 10mg twice daily dose of Xeljanz… Continue reading Xeljanz and pulmonary embolism and thrombosis
Lemtrada – stroke and arterial dissection
Lemtrada is an intravenous medication used to treat multiple sclerosis. Since it was approved, patients have been suffering from strokes and arterial dissection. Adverse events prompted the FDA to issue a Drug Safety Communication warning of risk of strokes and tears in lining of arteries of the head and neck in MS patients who are… Continue reading Lemtrada – stroke and arterial dissection